Bendectin and Birth Defects
The Challenges of Mass Toxic Substances Litigation
1st Edition
Published on 13. January 2016
384 pages
978-1-5128-1641-9 (ISBN)
Description
Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation, comparing individual and collective forms of litigation, and illustrating the misunderstandings between scientists and lawyers about the role of science in providing evidence for the legal system.
More details
Language
English
Place of publication
Pennsylvania
United States
Target group
College/higher education
Professional and scholarly
ISBN-13
978-1-5128-1641-9 (9781512816419)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Book
01/1998
University of Pennsylvania Press
€37.50
Shipment within 10-20 days
Person
Michael D. Green is Professor of Law at the University of Iowa.
Content
- Cover
- Title
- Copyright
- Contents
- Preface
- Acknowledgments
- 1 A Birth Defect Child Is Born
- 2 Locating Bendectin Within the Mass Toxic Landscape
- 3 The Science of Determining Toxic Causation
- 4 The Food and Drug Administration
- 5 The Wm. S. Merrell Company
- 6 A Mother's Quest
- 7 The Mekdeci Case
- 8 The Unraveling of Mekdeci
- 9 The Proliferation of Bendectin Litigation
- 10 Litigating a Multidistrict Case
- 11 The Withdrawal of Bendectin
- 12 Forging a Mass Toxic Substances Trial
- 13 The Settlement and Unsettlement of MDL-486
- 14 The MDL-486 Trial
- 15 Aggregative Procedure in Mass Toxic Substances Litigation
- 16 The Third Phase of Bendectin Litigation: Oxendine, Richardson, and the Individual Trials
- 17 The Legacy of Bendectin for Toxic Causation Law
- 18 The Lessons and Non-Lessons of Bendectin Litigation
- Selected Bibliography
- Index
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- R
- S
- T
- V
- W
- Y
